The price of Incruse Ellipta can vary based on factors such as dosage, form, insurance coverage, and pharmacy. A typical 30-day supply of Incruse Ellipta may cost around $400 to $500 without insurance [1].
How can I get a lower price for Incruse Ellipta?
Patients may be able to reduce the cost of Incruse Ellipta through savings cards or copay assistance programs offered by the manufacturer, GSK. Eligibility for these programs typically depends on insurance status and specific plan details [1]. Additionally, comparing prices across different pharmacies can help identify more affordable options.
What is Incruse Ellipta used for?
Incruse Ellipta is a once-daily inhaled medication prescribed for the long-term maintenance treatment of bronchospasm and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) [2]. It is not intended for the relief of acute bronchospasm [2].
How does Incruse Ellipta work?
Incruse Ellipta contains the active ingredient umeclidinium, which is a long-acting muscarinic antagonist (LAMA). It works by blocking the action of acetylcholine on airway smooth muscle, leading to bronchodilation and making it easier to breathe [3].
When does the patent for Incruse Ellipta expire?
The patent expiration date for Incruse Ellipta is a key factor in the potential introduction of generic alternatives. Information on patent status and exclusivity periods is available through resources like DrugPatentWatch.com [4].
What are the common side effects of Incruse Ellipta?
Common side effects associated with Incruse Ellipta include nasopharyngitis (common cold symptoms), headache, and upper respiratory tract infection [2]. Less common but serious side effects can involve urinary retention, acute angle glaucoma, and paradoxical bronchospasm [2].
What is the dosage and administration of Incruse Ellipta?
The recommended dose of Incruse Ellipta is one inhalation once daily [2]. It is administered using the Ellipta inhaler device [2].
Can Incruse Ellipta be used with other COPD medications?
Incruse Ellipta is often prescribed as a single maintenance bronchodilator but can also be used in combination with other COPD therapies, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids, depending on the patient's needs and treatment plan [2].
What clinical data supports the use of Incruse Ellipta?
Clinical trials have demonstrated that Incruse Ellipta effectively reduces the rate of moderate to severe COPD exacerbations and improves lung function [2]. These studies have been instrumental in its approval for COPD management.
Are there alternative treatments for COPD?
Alternative treatments for COPD include other classes of bronchodilators such as short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and other long-acting muscarinic antagonists (LAMAs). In some cases, combination therapies and inhaled corticosteroids may also be used [2].
What is the regulatory status of Incruse Ellipta?
Incruse Ellipta is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the maintenance treatment of COPD [2].
Sources:
1. GoodRx
2. Incruse Ellipta Prescribing Information
3. U.S. National Library of Medicine - Drugs and Supplements
4. DrugPatentWatch.com